Alnylam Pharmaceuticals, Inc. (ALNY) to Release Earnings on Tuesday
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is scheduled to release its earnings data after the market closes on Tuesday, October 31st. Analysts expect Alnylam Pharmaceuticals to post earnings of ($1.26) per share for the quarter.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm’s quarterly revenue was up 82.9% on a year-over-year basis. During the same period in the previous year, the business posted ($1.05) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $-5.14 EPS for the current fiscal year and $-5.66 EPS for the next fiscal year.
Alnylam Pharmaceuticals, Inc. (ALNY) opened at 117.735 on Tuesday. The firm’s market cap is $10.80 billion. Alnylam Pharmaceuticals, Inc. has a 1-year low of $31.38 and a 1-year high of $126.16. The firm’s 50-day moving average is $105.95 and its 200 day moving average is $80.68.
In related news, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.
Several research analysts recently issued reports on ALNY shares. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the stock a “buy” rating in a research report on Tuesday, June 27th. Chardan Capital reissued a “buy” rating and set a $131.00 price objective (up from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. BidaskClub cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 29th. Ladenburg Thalmann Financial Services set a $90.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Zacks Investment Research raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 price objective for the company in a report on Wednesday, July 12th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. Alnylam Pharmaceuticals has an average rating of “Hold” and an average target price of $100.80.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.